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VISUAL OUTCOMES IN  
REFRACTIVE SURGERY OUTLIER CANDIDATES 
 
CHRISTOPHER A. POCHAT 
ABSTRACT 
BACKGROUND: Refractive surgery has become a popular method of treating and 
reducing refractive errors. Some of the most common types	of	corneal-based	refractive	surgery	are	Laser	In	Situ	Keratomileusis	(LASIK),	Laser	Epithelial	Keratomileusis	(LASEK),	and	Photorefractive	Keratectomy	(PRK).	Advanced	Surface	Ablation	(ASA)	is	an	umbrella	term	which	refers	to	both	LASEK	and	PRK.	The	current	literature	lacks	analysis	of	high	refractive	errors	with	controls.	 
OBJECTIVES: To fill gaps in the current literature regrading outliers with high 
refractive errors by comparing their outcomes to those with low-moderate refractive 
errors. Additionally, to determine if LASIK or ASA offers superior results for those with 
high refractive errors and to determine those	with	different	high	refractive	errors	have	similar	refractive	surgery	outcomes. 
METHODS: A retrospective chart review identified 46 eyes with a preoperative 
spherical component ≤ -8.50D, 63 eyes with preoperative spherical component ≥ + 
3.50D, and 54 eyes with a preoperative cylindrical component ≥ -3.50D which met the 
criteria for inclusion in the high refractive error cohorts. Each eye was age-matched to a 
control with a low-moderate amount of its respective refractive error. Quantitative 
variables were analyzed with t-tests and single-factor analysis of variance. Qualitative 
variables were analyzed with chi-squared tests. Postoperative	uncorrected	distance	
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visual	acuity	(UCDVA)	was	used	as	the	primary	determinant	of	visual	outcomes	and	postoperative	best	corrected	visual	acuity	(BCDVA)	was	used	as	the	secondary	determinant	of	visual	outcomes.	Postoperative	manifest	refractions	supplemented	the	analysis.	Changes	in	BCDVA	between	pre-	and	postoperative	measurements,	with	particular	attention	to	loss	of	Snellen	lines,	were	used	as	determinants	of	safety. 
RESULTS: The	postoperative	UCDVA	and	BCDVA	of	the	myopia	cohort	was	significantly	worse	than	that	of	the	myopia	control	group	(p	=	0.038	and	p	=	
0.0029).	There	was	no	significant	difference	the	safety	profiles	of	the	myopia	cohort	and	control	group	(p	=	0.99).	The	postoperative	UCDVA	of	the	hyperopia	cohort	was	significantly	worse	than	that	of	the	hyperopia	control	group	(p	=	0.0069).	There	was	no	significant	difference	in	the	safety	profiles	of	the	hyperopia	cohort	and	control	group	(p	=	0.96).	The	postoperative	UCDVA	of	the	astigmatism	cohort	was	significantly	worse	than	that	of	the	astigmatism	control	group	(p	=	0.0014).	There	was	no	significant	difference	the	safety	profiles	of	the	myopia	cohort	and	control	group	(p	=	0.99).	There	was	no	difference	between	postoperative	UCDVA	and	BCDVA	between	the	cohorts.	Neither	LASIK	nor	ASA	were	superior	to	the	other	in	terms	of	UCDVA	or	BCDVA	for	all	of	the	cohorts.	 
CONCLUSION: Refractive surgery, while safe, is not as effective for those requiring 
high amounts of visual correction compared to those requiring low amounts. Neither 
surgery type, LASIK nor ASA, offer superior results to those with high refractive errors.  
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INTRODUCTION 
 
 In the United States, over half of the adult population has some form of refractive 
error (Vitale et al.). Refractive errors are a group of conditions relating to the eye which 
impair an individual’s sight. The main types of refractive error are myopia, hyperopia, 
astigmatism, and presbyopia. Traditionally, refractive errors have been treated with 
spectacle lenses which are placed in front of the eye and correct for the error. Contact 
lenses may also treat refractive error, if deemed appropriate for an individual. Since 1948, 
refractive surgery procedures have been developed to reduce an individual’s reliance on 
corrective lenses and with the aid of advances in laser technologies have become a safe, 
effective, and popular choice for many with refractive errors (Reinstein, Archer, et al.). 
 
Refractive Errors 
In normal vision, also known as emmetropia, light passes through the structures of 
the eye and are focused onto the retina. The human eye is primarily a two-lens system in 
which the refractive power of the cornea and crystalline lens work in concert to focus 
light directly onto the retina. The cornea is responsible for the majority of the eye’s 
refractive power. The lens’s shape can be modified by the ciliary body which leads to 
adjustment of the lens’s refractive power. This process is known as accommodation. 
Once light rays reach the retina, rod and cone cells are stimulated to generate electrical 
impulses which are transmitted to the brain. The brain in turn perceives these impulses as 
an image (How Your Eyes Work). Refractive errors occur when light entering the eye is 
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not focused properly by the cornea and/or lens onto the retina. This leads to the brain 
perceiving a blurry image.  
Myopia is colloquially known as nearsightedness; myopes, individuals with 
myopia, see objects close to them (~14”) well and objects further from them (>~20’) 
appear to be blurry. Myopia occurs when rays of light are focused in front of the retina 
(Figure 1). This is due to the refractive power of the eye is too high which moves the 
focal point anterior to the retina. Typically, an increased axial length, the distance 
anterior to posterior, of the eye and an increase in the “steepness”, curvature, of the 
cornea are related to myopia (Bastawrous et al.). Treatment of myopia traditionally 
involves the use of a spherical, divergent (concave) lens placed in front of the eye to shift 
the focal point posteriorly onto the retina. This lens would have a negative power in 
diopters (D), and thus myopes are described as having a negative spherical prescription 
(Stein et al.). The 1999–2004 National Health and Nutrition Examination Survey 
estimated the prevalence of myopia to be 33.1% (Stein et al.). 
 
	
Figure 1. The Myopic Eye. Light rays passing through the eye are focused to a point anterior to the retina.  
The cornea and crystalline lens are labeled (Stein et al.). 	et	
Cornea	 Lens	
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In contrast, individuals with hyperopia, hyperopes, can typically see objects in the 
distance (>20’ from the eye) clearly while objects nearby appear to be blurry. This can 
vary between individuals dependent upon their age and degree of hyperopia. The 
structures of the eye focus rays of light too weakly producing a focal point posterior to 
the retina (Figure 2). Hyperopes are typically described as having a short eye, one with a 
decreased axial length, or a “flat” cornea, one with decreased curvature (Bastawrous et 
al.). When a spherical converging (convex) lens is placed in front of a hyperopic eye the 
focal point is shifted anteriorly onto the retina. Hyperopes are said to have a positive 
spherical prescription as the lens used to correct their vision has a positive power in 
diopters (Stein et al.). It has been estimated that 3.6% of Americans are affected by 
hyperopia (Vitale et al.). 
 
Astigmatism arises when light rays are not refracted equally in all directions while 
passing through the eye, in these cases a single focal point is not achieved. Typically, an 
individual with uncorrected astigmatism will complain of blurriness of both near and far 
	
Figure 2. The Hyperopic Eye. Light rays passing through the eye are focused to a point posterior to the 
retina (Stein et al.). 	
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objects. The unequal refraction is typically due to the radius of curvature of the cornea is 
not uniform in all directions (Figure 3). Regular astigmatism can be defined as an 
astigmatism which is able to be corrected by a cylindrical lens. There are various 
subtypes of regular astigmatism in which an astigmatism may be compounded with 
myopia and/or hyperopia. In simple astigmatism one meridian of light is focused onto the 
retina while the complimentary meridian is focused either in front of the retina (simple 
myopic astigmatism) or behind the retina (simple hyperopic astigmatism). In compound 
astigmatism both meridians’ focal points land in front of the retina (compound myopic 
astigmatism) or behind the retina (compound hyperopic astigmatism). In mixed 
astigmatism on meridian’s focal point is in front of the retina while the complimentary 
meridian’s focal point lands behind the retina (Stein et al.). Individuals with astigmatism 
have a cylindrical component to their prescription. Historically, optometrists have used 
negative cylindrical power and ophthalmologists have worked with positive cylindrical 
power. However, due to the belief that it is easier to mistakenly overcorrect a myope 
when working with positive cylinder, refractive surgeons typically use negative cylinder. 
Approximately 36.2% of Americans are effected by some form of astigmatism (Vitale et 
al.). 
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 Presbyopia is similar to hyperopia, in that it causes objects nearby to appear 
blurry but objects in the distance are not affected. It is caused by a loss of accommodative 
power, that is the crystalline lens becomes less flexible as an individual ages and the eye 
loses the ability to focus on nearby objects. Presbyopia effects virtually all adults over 40 
years old.  
	
Figure 3. Types of Regular Astigmatism. The red lines represent light rays in the vertical meridian and the 
blue line represent light rays in the horizontal meridian. A) Simple hyperopic astigmatism, the vertical rays 
are emmetropic while the horizontal rays are focused behind the retina. B) Simple myopic astigmatism, the 
vertical rays are emmetropic while the horizontal rays are focused in front of the retina. C) Compound 
hyperopic astigmatism, both the vertical and horizontal rays are focused behind the retina. D) Compound 
myopic astigmatism, both the vertical and horizontal rays are focused in front of the retina. E) Mixed 
astigmatism, vertical rays are focused behind the retina and horizontal rays are focused in front of the 
retina. (Stein et al.)  	
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Refractive Surgery 
Refractive surgery is a popular alternative to corrective lenses for the treatment of 
refractive errors. Typically, this group of procedures is focused on the cornea, but can 
also involve the crystalline lens. The cornea is the most anterior structure of the eye and 
is comprised of three main layers: anteriorly the epithelium, the corneal stroma, and 
posteriorly the endothelium. Bowman’s membrane separates the epithelium from the 
stroma while Descemet's membrane separates the stroma and the endothelium. The 
epithelium provides a smooth refractive surface for the eye while serving as an 
immunologic barrier (Huang and Chen). The corneal epithelium is stratified squamous 
non-keratinized and is regenerated by stem cells from the corneal limbus around its 
periphery. The stromal layer comprises a majority of the cornea’s thickness. Due to its 
composition, mainly connective tissue, it is responsible for the cornea’s integrity. The 
endothelium separates the cornea from the anterior chamber and aqueous fluid; it is 
responsible for the cornea’s relative dehydration via an active sodium potassium-
adenosine triphosphatase pump which allows the cornea to remain transparent (Huang 
and Chen). 
Three common types of corneal-based refractive surgery are Laser In Situ 
Keratomileusis (LASIK), Laser Epithelial Keratomileusis (LASEK), and Photorefractive 
Keratectomy (PRK). These are laser based refractive surgeries which utilize an excimer 
laser to re-shape the corneal stroma. The laser utilizes excited gas dimers to produce 
photons which are fired in a pulsatile fashion at the corneal stroma. This breaks 
molecular bonds and causes a controlled amount of tissue to be ablated (Huang and 
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Chen). In general, the aim of a treating a myopic eye is to flatten the cornea, reducing its 
radius of curvature. The aim of treating a hyperopic eye is to steepen the cornea, 
increasing its radius of curvature.  
Originally the amount and pattern of ablation was governed by the patient’s 
spherical and cylindrical correction. Wavefront-guided and wavefront-optimized 
treatment patterns have been utilized to “customize” a patient’s treatment. Wavefront 
based treatments measure light as it passes through the eye to determine a patient’s 
refractive error due to lower-order aberrations (sphere and cylinder) as well as higher-
order aberrations. Wavefront systems reportedly offer improved visual outcomes, such as 
visual acuity (VA) and halos/starbursts, over traditional treatments (Netto et al.). 
LASIK, LASEK, and PRK surgeries mainly differ in how the corneal stoma is 
accessed (Figure 4). In LASIK, a microkeratome or femtosecond laser are utilized to 
create a flap of tissue with a hinge. This flap can range from 90 to 150 microns in 
thickness and is comprised of the corneal epithelium and part of the stromal layer. Flap 
creation with the femtosecond laser, so-called “bladeless LASIK”, is preferred as it offers 
better flap thickness predictability as well as a faster recovery time (Huang and Chen). 
After ablation the flap is laid back in place over the reshaped stroma. LASEK also 
involves the use of a flap, however it is much thinner than a LASIK flap as it is solely 
comprised of the epithelium and does not invade the corneal stroma. A LASEK flap is 
created via controlled application of an alcohol solution to the cornea which loosens the 
epithelium so that the surgeon may lift it as a either a single flap or in parts (Taneri et al.). 
The epithelium is replaced after ablation and a bandage contact lens is placed over the 
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cornea while a new epithelial layer grows. PRK does not involve the use of a flap, instead 
the epithelium is completely removed with an alcohol solution, blade, and/or brush. A 
bandage contact lens is placed over the cornea subsequent to ablation. Due to their 
similarities, LASEK and PRK surgeries will be grouped and referred to as Advanced 
Surface Ablation (ASA) for the remainder of this thesis (Taneri et al.). 
 
	
Figure 4. The Cornea in	Refractive Surgery A) An intact cross section of the cornea. B) PRK: The 
epithelium has been completely removed, exposing the corneal stroma for ablation. C) LASEK: The 
epithelium is removed but preserved as a sheet to be replaced after ablation of the stromal layer. D) LASIK: 
A partial thickness flap, consisting of the epithelium and some of the stroma, is cut with a hinge. Subsequent 
to ablation the flap is laid back down over the corneal stroma (Bastawrous et al.). 	
	9 
Candidacy for Refractive Surgery  
 All patients with refractive errors are not candidates for refractive surgery. 
Preoperative screening and testing are paramount to selecting proper candidates for the 
proper procedure type. A good candidate for surgery will have a stable refraction myopia 
≤ -12.00D or hyperopia ≤ +6.00D, and/or astigmatism ≤ 5.00D (Huang and Chen). 
Absolute ocular contraindications to surgery are an unstable refraction (>0.50D change in 
sphere or cylinder in the past year), keratoconus, herpetic keratitis, corneal dystrophy or 
degeneration, cataract, uncontrolled glaucoma, active infection or inflammation, and 
other pre-existing corneal or anterior segment pathologies. Absolute medical 
contraindications include history of keloid formation, pregnancy or lactation, 
uncontrolled autoimmune disease, and immunosuppression or immunocompromised 
status (Huang and Chen). A stable refraction is imperative because if a patient’s 
prescription is fluctuating, they are more likely to require re-treatment (enhancement) 
after surgery. Keratoconus is a non-inflammatory disorder which causes progressive 
thinning of the cornea. It is a contraindication for refractive surgery due to the risk of 
postoperative keratectasia, increasing myopia/astigmatism due to progressive steepening 
of the cornea (Ormonde). Preoperative corneal topography is essential to the screening 
for sub-clinical keratoconus. Patients with a history of herpes keratitis are advised against 
surgery as it may reactivate their infection.  
 Not all patients are candidates for both LASIK and ASA. Due to the creation of 
the flap during LASIK, there is less of the stromal bed available for alteration in 
comparison to ASA. Important considerations for the refractive surgeon in choosing a 
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surgery type are the percent of tissue altered (PTA) and residual stromal bed (RSB). The 
PTA is defined as !"#$	&'()*+,+--	((/	#$$"()#0"+)2	&'()*,+--	3/	435,+#	60"#7+84+,75#"	435,+#"	&'()*,+--  and the RSB is 
the thickness of the stromal layer after surgery. If patient has a theoretical PTA > 40% of 
theoretical RSB < 300 microns they are at an increased risk of corneal ectasia (Santhiago 
et al.). The surgeon must use corneal pachymetry, a measurement of the cornea’s 
thickness via either a pachymeter or corneal topographer, to determine if a patient is a 
candidate for LASIK.  
 If a patient is a candidate for both LASIK and ASA, the question becomes which 
surgery would provide the patient the best outcome. The current literature is lacking in 
good evidence randomized control trials comparing LASIK and ASA surgeries for 
myopia and hyperopia (Kuryan et al.; Li et al.; Settas et al.; Shortt et al.). The literature is 
even more so lacking in trials comparing different surgery types specifically in patients 
with high degrees of refractive error. A literature review revealed no studies comparing 
LASIK to either PRK or LASEK for eyes with high hyperopia, one study comparing 
LASIK to PRK for high astigmatism, and three comparing LASIK to ASA surgeries for 
high myopia (Katz et al.). The studies comparing LASIK to ASA surgeries vary greatly 
in their results, with 19.1% to 60% of eyes achieving 20/20 vision or better and 55.7% to 
76% achieving 20/40 vision or better uncorrected (Hersh et al.; Kim et al.; Helmy et al.). 
They also disagree if there is a superior surgery for highly myopic eyes, with Hersh et al. 
finding no difference in efficacy between LASIK and PRK, while Kim et al. and Helmy 
et al. found LASIK to be superior to ASA surgeries. Katz et al. found LASIK and PRK to 
be similarly effective for the treatment of high astigmatism.  
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 Similarly, while general reports of visual outcomes of various groupings of 
patients are plentiful, there is a great lack in the literature of high refractive error groups 
being directly compared to low refractive error groups of the same population. The 
individual reports of high refractive error groupings vary greatly in outcomes, as do 
reports of low-moderate refractive error groups. Huang and Chen report ranges for 
moderate to high myopia 10% to 47% of eyes achieve 20/20 vision or better and 55% to 
94% of eyes achieve 20/40 vision or better uncorrected. This thesis aims to fill in these 
gaps in the current literature.   	  
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OBJECTIVES 
The purpose of this thesis was to fill gaps within the current literature on the 
visual outcomes of outlier candidates for refractive surgery; those with high degrees of 
either myopia, hyperopia, or astigmatism. The specific objectives were to: 1) Compare 
those with high refractive errors with those with low-moderate refractive errors in terms 
of efficacy and safety of treatment 2) Determine if LASIK or ASA is more efficacious to 
those with high refractive errors 3) Determine if those with different high refractive 
errors have similar refractive surgery outcomes.  
The hypothesis tested was that refractive surgery for the high refractive error 
groups would not be as efficacious nor as safe as for their low refractive error peers. 
Furthermore, it was hypothesized that ASA surgery would be more beneficial for the high 
astigmatism cohort, LASIK surgery would be more beneficial for the high myopia and 
high hyperopia cohorts. Lastly, no difference in outcomes was expected between the high 
refractive error cohorts. 
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METHODS 
Study Design 
 A retrospective chart review was performed via NextGen electronic health record 
software (Version 5.9.1.92) on all patients who underwent laser vision correction 
(LASIK, LASEK, or PRK) at Boston Eye Group/Boston Laser from December 2008 – 
December 2018. The follow-up period for the study was selected to be 12 months ±3 
months from the date of surgery. All eyes were identified via their preoperative manifest 
refraction.  Manifest refraction is the standard, if subjective, measurement of a patient’s 
refractive error using a series of lenses with a phoropter. Myopia cohort candidates were 
identified as having a preoperative manifest refraction with a spherical component ≤ -
8.50D. Myopia control candidates were identified as having a preoperative manifest 
refraction with a spherical component < -0.50D and ≥ -4.00D. Hyperopia cohort 
candidates were identified as having a preoperative manifest refraction with a spherical 
component ≥ + 3.50D. Hyperopia control candidates were identified as having a 
preoperative manifest refraction with a spherical component > +0.50D and < +2.00D. 
Astigmatism cohort candidates were identified as having a preoperative manifest 
refraction with a cylinder component ≥ -3.50D. Astigmatism control candidates were 
identified as having a preoperative manifest refraction with a cylinder component < -
0.25D and ≥ -1.50D. Control eyes were selected to match each cohort eye for age on day 
of surgery; if a control eye of the same age was unavailable or did not meet inclusion 
criteria, the next closest control eye in age was selected. If a candidate had multiple 
follow-ups within the follow-up period data from the visit closest in time to 12 months 
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from surgery was used. If a candidate for one of the high refractive error cohorts 
underwent an enhancement surgery prior to 9 months after their initial surgery the results 
of their original surgery were included using a “last observation carried forward” 
technique. The last postoperative data available prior to enhancement surgery was used as 
their one-year endpoint data. These patients were included to reduce bias against poor 
results that would be introduced by excluding them.  Follow-up time was determined in 
days using https://www.timeanddate.com/date/duration.html.  
 
Exclusion Criteria 
• No follow-up visit within 12 ± 3 months from day of surgery 
• Previous eye surgery on the operative eye 
• Missing pre- or postoperative data from the Electronic Health Record 
• Eyes that underwent phototherapeutic keratectomy 
• Eyes that required initial treatment in two stages (two surgical dates for the initial 
treatment of one eye) 
• Patient age <18 years old  
• Eyes with a target post-operative refraction other than a 0.00 spherical equivalent  
 
Preoperative Consultation 
All patients underwent a preoperative consultation with a board-certified 
ophthalmologist or optometrist. This consultation is standardized for all patients who 
wish to pursue refractive surgery with Boston Eye Group/Boson Laser. It is typically	
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carried	out	by	staff	at	Boston	Eye	Group	and	referrals	for	surgery	still	undergo	the	testing	at	Boston	Eye	Group. All patients are asked to refrain from soft-contact use for 1 
week and hard-contact use for 3 weeks prior to consultation. Initial testing includes an 
auto-refraction, auto-keratometry, ocular dominance, corneal topography, corneal 
pachymetry, ZoneQuick Phenol Red Thread Tear Test, ocular tonometry (via non-contact 
tonometry, Tono-pen, or Goldman applanation), and scotopic pupillometry.  
Spectacle-corrected distance visual acuity (DVA) is measured with a Snellen 
chart, as well as uncorrected distance visual acuity (UCDVA) and uncorrected near visual 
acuity. A manifest refraction is performed to determine the patient’s preoperative 
prescription as well as their best-corrected distance visual acuity (BCDVA). Wavescans 
are performed as ordered by the attending physician. All patients are dilated and undergo 
a cycloplegic refraction, slit-lamp examination, and dilated fundus exam. The physician 
uses all available information, including personal judgment, to determine what, if any, 
refractive surgery a particular patient may be a candidate for (Figure 5).  
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Figure 5. Refractive Surgery Algorithms. These flow charts are an example of a conservative practice 
pattern of Samir Melki M.D. Ph.D. Not all steps or cut off values are evidenced based nor absolute 
contraindications, they merely generalize the thought process a surgeon may take when deciding what 
surgery type a patient is a candidate for. (Sph = spherical power, ICL = implantable collamar lens, I-S Ratio = 
inferior to superior corneal power ratio, Risk Factor Index = proprietary risk gauging index (Patient Age < 26 
years old = 0.5; max preoperative keratometry > 46 = 1.0; difference between right and left eye keratometry > 1.5  
= 1.0; positive family history of keratoconus = 1.0; I-S Ratio > 1.5 = 2.0), RSB = residual stromal bed, OZ = 
optical zone, PTA = Percent of Tissue Altered, ASA = advanced surface ablation, LASIK = Laser In Situ 
Keratomileusis, Post-Op K = Maximum Calculated Postoperative Keratometry,) 
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Day of Surgery  
 All patients met with their surgeon either prior to the day of surgery or when they 
arrive to the surgery site; they were also given the opportunity to meet with their surgeon 
again at any point during the preoperative process. All patients signed informed consent 
forms detailing the potential benefits, risks, and alternatives of laser vision correction. 
Patients were instructed to discontinue soft-contact lens use one week and hard-contact 
lens use three weeks prior to the surgical date. Any repeat testing was performed as 
ordered by the surgeon, e.g. repeat manifest refraction due to discrepancies in earlier 
refractions and repeat corneal topography due to contact lens use prior to previous 
topography. Patients were educated on the steps of their specific procedure, postoperative 
care, and postoperative medication use. A time-out was called with the patient to confirm 
the operative eye(s), the procedure(s), the aim for each eye, all the patient’s questions 
have been answered, the patient’s postoperative transportation, the patient has their 
postoperative medication, and the patient has discontinued contact lens use for the 
appropriate time period. Eye(s) not being operated upon were covered with an eye shield. 
Patients who were scheduled for different procedures on each eye had their forehead 
marked to denote the correct procedure for each eye. Patients were given preoperative 
medication 20 minutes prior to the anticipated surgical time: Ciprofloxacin 
Hydrochloride Ophthalmic Solution 0.3% One drop instilled into the operative eye(s), 
Ketorolac Ophthalmic Suspension 0.5% One drop instilled into the operative eye(s), and 
Diazepam 5mg one tablet by mouth. If the patient’s refraction contained more than 1.25D 
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of cylinder their eye was marked with a sterile surgical marker to ensure proper laser 
alignment. 
 Each patient was asked to confirm their full name and date of birth prior to being 
brought into the surgical suite. Patients were laid on supine on the operative bed with a 
surgical cushion placed below their knees and a hairnet was placed over their head. 
Proparacaine Hydrochloride Ophthalmic Solution 1% was instilled into the operative 
eye(s) as a topical anesthetic. The operative eye(s) were sterilized by topical application 
of Betadine 5% to the periocular area. A time-out was called and patients confirmed their 
last name, date of birth, operative eye(s), procedure per eye, if they desired monovision, 
and the aim of each eye. The time-out was continued by the surgeon and assistant who 
confirmed the patient’s identity via a photograph on file and the treatment plan inputted 
to the laser. The following describes the different intra-operative procedures for LASIK 
and ASA.  
 LASIK 
 All LASIK flaps were created using the IntraLase iFS60 or FS150 Femtosecond 
Laser. The standard parameters were a superior hinge position, 9.2 mm in diameter, and a 
thickness of 100 microns. These parameters may have been changed at the surgeon’s 
discretion due to corneal topography and/or pachymetry. Suction was applied to the eye 
prior to docking into the laser interface. The patient’s cornea was applanated flat and the 
pupil was centered with fine adjustments to the laser’s position. The patient was 
undocked from the laser and the patient interface was discarded.  
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The operative bed was repositioned under the excimer laser, either the VISX 
STAR S4 IR or WaveLight EX500. A Tegaderm (3MTM) was placed over the upper 
eyelid to hold the eyelashes away from the eye and a speculum was placed to ensure the 
eye remained open. A mark was placed at the edge of the LASIK flap at the 5 o’clock 
with a sterile surgical marker. The eye was irrigated with balanced salt solution and 
proparacaine hydrochloride ophthalmic solution 1% was instilled to maintain proper 
anesthetization. The eye was dried with a Weck-Cell sponge (BVI). Corneal pachymetry 
was measured either with a handheld pachymeter or with the excimer laser system and 
was read out loud to the surgeon. The LASIK flap was lifted with a LASIK spatula and 
the exposed stroma was dried with a Weck-Cell sponge. A “flap-lift” pachymetry was 
measured in the same manner as previously described and verbally called out. The 
surgeon confirmed that the surgery was safe to proceed. The surgeon centered the pupil 
and adjusted the head as needed. The surgeon then fired the excimer laser to ablate the 
corneal stroma. After completion of the treatment, the surgeon repositioned the LASIK 
flap and irrigated the corneal surface and stromal bed with balanced salt solution. A 
Weck-Cell sponge was used to dry the excess fluid and remove fluid from the LASIK 
flap “gutter”. Two drops of Gatifloxacin- Prednisolone 0.5%-0.1% ophthalmic solution 
were instilled in the operative eye. The patient was escorted to a dimly lit exam room 
where they remained at rest for 30 minutes. The operative eye was examined with a silt-
lamp to ensure the LASIK flap was in position. An eye shield was placed over the 
operative eye and the patient was discharged from the surgical site to the care of their 
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postoperative transportation. All patients were instructed with lie down with their eyes 
closed for a minimum of four hours once they arrived home. 
ASA 
The operative bed was repositioned under the excimer laser, either the VISX 
STAR S4 IR or WaveLight EX500. A Tegaderm was placed over the upper eyelid to hold 
the eyelashes away from the eye and a speculum was placed to ensure the eye remained 
open. Proparacaine hydrochloride ophthalmic solution 1% was instilled to maintain 
proper anesthetization. The eye was dried with a Weck-Cell sponge. A 9mm ring well 
was positioned centrally on the cornea and filled with a previously prepared 20% ethanol 
solution. The solution was applied to the cornea for 40 seconds before being absorbed 
with a Weck-Cell sponge. The eye was irrigated with 5 mL of 0.9% saline and dried with 
a Weck-Cell sponge.  
Eyes undergoing LASEK had their epithelium repositioned outside of the 
treatment area. The surgeon centered the pupil and adjusted the head as needed. The 
surgeon the fired the excimer laser to ablate the corneal stroma. The epithelium was then 
repositioned to cover the exposed stromal layer.  
Eyes undergoing PRK had their epithelium completely removed. The surgeon 
centered the pupil and adjusted the head as needed. The surgeon the fired the excimer 
laser to ablate the corneal stroma. If indicated, a corneal light shield soaked with 
mitomycin-C was applied for an amount of time dependent on the amount of tissue 
ablated. The eye was irrigated with 5 mL of cold 0.9% saline and dried with a Weck-Cell 
sponge.  
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Regardless of procedure type, a bandage contact lens was placed on the eye. Two 
drops of Gatifloxacin- Prednisolone 0.5%-0.1% ophthalmic solution and one drop of 
cyclopentolate hydrochloride ophthalmic solution 1% were instilled in the operative eye. 
The patient was discharged from the surgical site to the care of their postoperative 
transportation.  
 
Postoperative Care 
 All patients were given printed postoperative care instructions. Postoperative 
limitations and precautions included but were not limited to: no squinting, squeezing, or 
rubbing the operative eye and no heavy lifting for 24 hours; keep exercise light and no 
sunscreen, lotion, or moisturize near the operative eye(s) for one week; no contact sports, 
swimming, hot tub, sauna, or jacuzzi for two weeks. Patients were instructed to wear an 
eye shield over their operative eye(s) while sleeping for one week.  
 For eyes which underwent LASIK the following postoperative regiment was 
prescribed. Prednisolone Acetate 1% Ophthalmic Suspension one drop every hour on the 
day of surgery and the two following days, then four drops per day for two days, then 
stop. Moxifloxacin hydrochloride ophthalmic solution 0.5% four drops per day the day of 
surgery and following 4 days, then stop. Liberal use of preservative-free artificial tears 
was strongly encouraged. Patients were instructed to wait 5 minutes before instilling a 
drop a different medication into the same eye. Patients were instructed to only using the 
drops during their waking hours.  
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For eyes which underwent ASA the following postoperative regiment was 
prescribed. Prednisolone acetate 1% ophthalmic suspension four drops per day for one 
week, then three drops per day for one week, then two drops per day for one week, then 
one drop per day for one week, then stop. Moxifloxacin hydrochloride ophthalmic 
Solution 0.5% four drops per day until instructed to stop (typically after one week and 
removal of the bandage contact lens). Nepafenac 0.1% ophthalmic suspension 1 drop as 
needed for discomfort, up to two times per day. Vitamin C 1,000 mg per day for three 
months to aid in corneal healing and prevent scar formation. Liberal use of preservative-
free artificial tears was strongly encouraged. Patients were instructed to wait 5 minutes 
before instilling a drop a different medication into the same eye. Patients were instructed 
to only use eyedrops during their waking hours. Patients were also offered a prescription 
for acetaminophen-codeine phosphate 300-30mg tablets for postoperative discomfort for 
use up to four times a day.  
All patients had follow-up appointments scheduled for one day after surgery. If a 
patient was “co-managed”, meaning they were under the concurrent care of an outside 
optometrist, they were returned to their optometrist’s care subsequent to their one-day 
follow-up. For all other patients, one-week, six-week, six-month, and one-year follow-
ups were recommended and attempted to schedule.  
At follow-up visits patients were asked if they had any complaints such as blurry 
vision, dryness, trouble driving, trouble reading, or halos. Patients’ uncorrected distance 
visual acuity (UCDVA) was checked monocularly and binocularly. If the patient 
underwent LASIK/ASA monovision, near visual acuity was checked. All patients had 
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auto-refraction performed at each follow-up visit. From the one-day follow-up for LASIK 
eyes and from the six-week follow-up for ASA eye, if the patient could not successfully 
read the 20/20 line on a Snellen chart or complained of blurry vision, a manifest 
refraction was performed. From the six-week follow-up onward intra-ocular pressure was 
measured. Additional testing was performed as ordered by the attending physician.  
 
Statistical Analysis 
Prior to analysis, all patient data was de-identified and assigned a reference 
number. The spherical equivalent of manifest refractions were calculated via the 
following formula: 𝑆𝐸	 = 	 (𝑆𝑝ℎ) +	?𝐶𝑦𝑙 2D E. Visual acuity (VA) data measured by the 
Snellen Chart were converted to log(MAR) for proper statistical analysis using Table 1 
(Holladay). Eyes with a postoperative UCDVA of 20/20, or better, that did not have a 
postoperative manifest refraction noted were considered to have a plano-spherical 
refraction (+0.00 -0.00x180) with a BCDVA the same as their UCDVA. Eyes that 
underwent an enhancement surgery prior to the study period had their last postoperative 
data available prior to enhancement surgery used as the data with a follow-up time of 365 
days. 
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The data analysis toolpak in Microsoft Excel for Mac 16.16.13 was used for all 
statistical analysis. Microsoft Excel for Mac 16.16.13 was also used for the creation of 
graphs. Quantitative variables were analyzed with t-tests and single-factor analysis of 
variance (ANOVA). Qualitative variables were analyzed with chi-squared tests. Two-
sample assuming unequal variances two-tailed t-tests were used to determine if there was 
a significant difference between different groups in the following variables: age at 
surgery, spherical power, cylindrical power, spherical equivalent, follow-up visit time, 
UCDVA, and BCDVA. Paired two-sample for means two-tailed t-tests were used to 
determine if there were significant differences between a group’s preoperative BCDVA 
and postoperative UCDVA as well as preoperative BCDVA and postoperative BCDVA. 
Chi-squared tests of independence were used to determine if there was a significant 
difference in distribution of sexes, surgery type, and gain/loss of BCDVA. Single-factor 
ANOVA tests were used to compare UCDVA and BCDVA between the cohorts.  
Table 1. Conversation Chart: Snellen to log(MAR). The log(MAR) values corresponding to relevant lines 
of the Snellen Visual Acuity Chart, as described by Holladay, 1997.  
Snellen	Equivalent	(feet)	 log(MAR)	Equivalent	20/15	 -0.125	20/20	 0	20/25	 0.1	20/30	 0.176	20/40	 0.3	20/50	 0.4	20/60	 0.477	20/70	 0.544	20/80	 0.6	20/100	 0.7	20/150	 0.875	20/200	 1.0	20/400	 1.3		
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The null hypothesis for all tests assumed equal means for continuous variables or 
equal distribution for categorical variables. A p-value of p < 0.05 was considered 
statistically significant. A p-value of p < 0.01 was considered very statistically 
significant. Any significant p-value led to rejection of the null hypothesis.  
 Postoperative UCDVA was used as the primary determinant of visual outcomes 
and postoperative BCDVA was used as the secondary determinant of visual outcomes. 
Postoperative manifest refractions supplemented the analysis. Changes in BCDVA 
between pre- and postoperative measurements, with particular attention to loss of Snellen 
lines, were used as determinants of safety (Huang and Chen). Visual acuities of 20/20, or 
better, were considered to be optimal results. While visual acuities worse than 20/40 were 
considered unsatisfactory. Visual acuities worse than 20/20 but 20/40 or better were 
considered satisfactory.  
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RESULTS 	
Myopia  
 There were 187 eyes (91 right and 96 left eyes) identified with a preoperative 
spherical power ≥ -8.50D. Of these, 48 eyes (22 right and 26 left eyes) met the criteria for 
inclusion in the myopia cohort. Excluded eyes are broken down in Table 2. There was a 
total of three eyes in the myopia cohort that underwent an enhancement procedure within 
the year following their surgery, accounting for 1.6% of the total eyes that were 
identified. The mean time after the original surgery that the enhancement procedure was 
performed was 266 ± 23 days.		
 
Preoperative 
 Of the 48 eyes included, 21 belonged to men and 27 belonged to women. Average 
preoperative manifest values and visual acuities are presented in Table 3. The myopia 
cohort had 4 eyes correctable to 20/15 on the Snellen scale, 40 eyes correctable to 20/20, 
three eyes correctable to 20/25, and one eye correctable to 20/30.  
Table 2: Myopia: Excluded Eyes. A breakdown of the eyes excluded from the myopia cohort and for what 
reason. Exclusion	Criteria	 Number	of	Eyes	Excluded	Non-Zero	Target	Refraction	 5	Previous	Surgical	Procedure	 1	Age	<	18	Years	Old	 1	Missing	Data	 3	No	Follow-Up	in	Study	Period	 129							
	27 
 
 The average age of the myopia control group at time of surgery did not differ 
from the myopia cohort, t(92) = 0.05, p = 0.96. Of the 48 eyes, 33 belonged to men and 
15 belonged to women; this distribution was not significantly different than the myopia 
cohort, c2(1, N=96) = 0.01, p = 0.91. The myopia control group was very significantly 
more myopic than the myopia cohort, t(92) = -61.60, p = 1.4x 10-76. The myopia control 
group had significantly more preoperative cylindrical power than the myopia cohort, 
t(78) = 2.25, p = 0.027. The mean preoperative spherical equivalent of the myopia 
control group was very significantly less than the myopia cohort, t(92) = -52.04, p = 4.9 x 
10-70. The myopia cohort and control group’s mean preoperative BCDVA did not differ 
significantly, t(73) = 0.31, p = 0.75.  
Table 3. Myopia: Preoperative Data. Mean preoperative data for the myopia cohort and control groups. 
Significance values for statistical analysis between groups are included below the respective data. (BCDVA = best 
corrected distance visual acuity) 	 Myopia	Cohort	 Myopia	Control	Group	Age	(Years)	 34	±	8	 35	±	8	p-value	 0.96	Spherical	Power	(D)	 -8.77	±	0.58	 -1.14	±	0.62	p-value	 1.4x	10-76	Cylindrical	Power	(D)	 -0.71	±	0.52	 -1.06	±	0.83	p-value	 0.027	Spherical	Equivalent	(D)	 -9.13	±	0.70	 -1.67	±	0.71	p-value	 4.9	x	10-70	BCDVA	(log(MAR))	 0.00	±	0.05	 0.00	±	0.03	p-value	 0.75	
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Postoperative 
 
Average postoperative manifest values and visual acuities are presented in Table 
4. The mean follow-up time was very significantly later for the myopia control group, 
t(80) = -4.06, p = 1.2 x 10-4. The myopia cohort had a very significant decrease in VA 
between the mean preoperative BCDVA and mean postoperative UCDVA, t(47) = -3.58, 
p = 8.2x 10-4. The myopia control group had no significant difference between mean 
preoperative BCDVA and mean postoperative UCDVA, t(47) = -1.54, p = 0.13. The 
UCDVA of the myopia cohort was significantly worse than that of the myopia control 
group, t(83) = 2.11, p = 0.038. The myopia cohort’s mean BCDVA was significantly 
worse postoperatively when compared to the preoperative mean, t(47) = -2.52, p = 0.015. 
There was no significant change to the myopia control group’s mean postoperative 
BCDVA when compared to their preoperative mean, t(47) =1.63, p = 0.11. The mean 
postoperative BCDVA of the myopia control group was very significantly better than the 
Table 4. Myopia: Postoperative Data. Mean postoperative data for the myopia cohort and control groups. 
Significance values for statistical analysis between groups are included below the respective data. (UCDVA = 
uncorrected distance visual acuity, BCDVA = best corrected distance visual acuity) 	 Myopia	Cohort	 Myopia	Control	Group	Follow-up	Time	(Days)	 361	±	62	 406	±	42	p-value	 1.2	x	10-4	Spherical	Power	(D)	 0.03	±	0.62	 -0.08	±	0.29	p-value	 p	=	0.18	Cylindrical	Power	(D)	 -0.29	±	0.47	 -0.13D	±	0.29	p-value	 p	=	0.034	Spherical	Equivalent	(D)	 -0.11D	±	0.63	 -0.14D	±	0.32	p-value	 0.65	UCDVA	(log(MAR))	 0.09	±	0.17	 0.02	±	0.12	p-value	 0.038	BCDVA	(log(MAR))	 0.02	±	0.06	 -0.01	±	0.04	p-value	 0.0029		
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myopia cohort, t(80) = 3.07, p = 0.0029. The breakdown of postoperative visual acuities 
is presented in Figure 6.  
 
The mean postoperative spherical power and spherical equivalents did not differ 
significantly between the myopia cohort and the myopia control group, t(67) = 1.37, p = 
0.18 and t(70) = 0.45, p = 0.65. The mean postoperative cylindrical power did differ 
significantly higher for the myopia cohort, t(75) = -2.16, p = 0.034.  
Safety 
 Changes in BCDVA are presented in Figure 7. There was no significant 
difference in the distribution of change of BCDVA between the myopia cohort and 
myopia control group, c2(3, N=96) = 0.01, p = 0.99. 
	
Figure 6. Myopia: Cohort vs Control Visual Acuities. Representations of the postoperative UCDVA and 
BCDVA of myopia cohort and myopia control group. The data are in terms of the percentage of eyes that 
achieved that VA or better. 
	30 
  
Surgery Type 
 In the myopia cohort there were 16 eyes that underwent LASIK and 32 eyes that 
underwent ASA. There was no significant difference in mean follow-up time between the 
surgery groups in the myopia cohort, t(26) = -1.47, p = 0.15. In the myopia control group, 
39 eyes underwent LASIK and 9 eyes underwent ASA; this was not significantly 
different from the surgery type distribution of the myopia cohort, c2(1, N=96) = 0.00, p = 
0.99. There was no significant difference in mean follow-up time between the surgery 
groups in the myopia control group, t(11) = 2.05, p = 0.06. 
 Within the myopia cohort, the mean postoperative UCDVA did not differ 
significantly between the eyes that underwent ASA (0.10 ± 0.18) and the eyes that 
underwent LASIK (0.05 ± 0.15), t(41) = 1.05, p = 0.30. In contrast, the mean 
postoperative UCDVA was significantly better in eyes the underwent ASA (-0.05 ±0.08) 
than eyes that underwent LASIK (0.04 ± 0.11) within the myopia control group, t(13) = -
2.50, p = 0.03. The mean postoperative BCDVA did not differ significantly between 
ASA eyes (0.02 ± 0.06) and LASIK eyes (0.03 ±0.05) within the myopia cohort, t(31) = -
	
Figure 7. Myopia: Change in BCDVA. Representation of the safety profile for both the myopia cohort 
and myopia control group. The data are presented in terms of the percentage of eyes that underwent 
that change in BCDVA. 
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0.54, p = 0.59. In the myopia control group, again eyes that underwent ASA performed 
significantly better than those that underwent LASIK with mean postoperative BCDVAs 
of -0.06 ± 0.07 and 0.00 ± 0.00 respectfully, t(7) = -2.65, p = 0.03.  
 When comparing eyes that underwent LASIK within the myopia cohort to LASIK 
eyes in the myopia control group, there was no significant difference between their mean 
postoperative UCDVA, t(26) =  0.31, p = 0.76. Nor was there a difference in the mean 
postoperative BCDVAs when comparing the myopia cohort and control group’s LASIK 
eyes, t(14) =  1.78, p = 0.10. The eyes that underwent ASA in the myopia control group 
had a very significantly better mean postoperative UCDVA compared to those in the 
myopia cohort, t(25) = 3.26, p = 0.003. Likewise the ASA eyes in the myopia control 
group had a significantly better mean postoperative BCDVA compared to those in the 
myopia cohort, t(10) =  3.00,  p = 0.013. 
 
Hyperopia 
There were 148 eyes (70 right and 78 left eyes) identified with a preoperative 
spherical power ≥ + 3.50D. Of these, 63 eyes (31 right and 32 left eyes) met the criteria 
for inclusion in the hyperopia cohort. Excluded eyes are broken down in Table 5.There 
was a total of 14 eyes in the hyperopia cohort that are known to have undergone an 
enhancement procedure within the year following their surgery, accounting for 9.5% of 
the total eyes that were identified. The mean time after the original surgery that the 
enhancement procedure was performed was 305 ± 120 days. 
	32 
 
Preoperative 
Of the 63 eyes included, 30 belonged to men and 33 belonged to women. Average 
preoperative manifest values and visual acuities are presented in table 6. The hyperopia 
cohort had 52 eyes correctable to 20/20 on the Snellen scale, six eyes correctable to 
20/25, four eyes correctable to 20/30, and one eye correctable to 20/50. 
 
The average age of the hyperopia control group at time of surgery did not differ 
significantly from the hyperopia cohort, t(121) = -0.23, p = 0.82. Of the 63 eyes, 35 
belonged to men and 28 belonged to women; this was not significantly different than the 
hyperopia cohort, c2(1, N=126) = 0.37, p = 0.54. The hyperopia cohort was very 
Table 5: Hyperopia: Excluded Eyes. A breakdown of the eyes excluded from the hyperopia cohort and for 
what reason. Exclusion	Criteria	 Number	of	Eyes	Excluded	Non-Zero	Target	Refraction	 6	Phototherapeutic	Keratectomy	 2	Missing	Data	 1	No	Follow-Up	in	Study	Period	 76							
Table 6. Hyperopia: Preoperative Data. Mean preoperative data for the hyperopia cohort and control groups. 
Significance values for statistical analysis between groups are included below the respective data. (BCDVA = 
best corrected distance visual acuity) 	 Hyperopia	Cohort	 Hyperopia	Control	Group	Age	(Years)	 42	±	12	 42	±	13	p-value	 0.54	Spherical	Power	(D)	 +4.11	±	0.64	 +1.33	±	0.40	p-value	 3.93	x	10-51	Cylindrical	Power	(D)	 -1.62	±	1.40	 -1.62	±	1.3	p-value	 0.88	Spherical	Equivalent	(D)	 +3.30	±	0.65	 +0.53	±	0.80	p-value	 5.2	x	10-41	BCDVA	(log(MAR))	 0.024	±	0.070	 0.013	±	0.043	p-value	 0.30		
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significantly more hyperopic than the hyperopia control group, t(103) = 28.84, p = 3.93 x 
10-51. The mean preoperative cylindrical did not differ significantly between the groups, 
t(121) = -0.15, p = 0.88. The mean preoperative spherical equivalent of the hyperopia 
control group very significantly less than the hyperopia cohort, t(119) = 20.58, p = 5.2 x 
10-41. The hyperopia control group and the hyperopia cohort did not differ in mean 
preoperative BCDVA, t(101) = 1.04, p = 0.30.  
Postoperative 
 
Average postoperative manifest values and visual acuities are presented in table 7. 
The mean follow-up time did not differ significantly between the groups, t(113) = -1.06, 
p = 0.29. The hyperopia cohort had a very significant decrease in VA between the mean 
preoperative BCDVA and mean postoperative UCDVA, t(62) = -5.47, p = 8.6 x 10-7. 
There was also a very significant decrease in VA between the hyperopia control group’s 
mean preoperative BCDVA and mean postoperative UCDVA, t(62) = -3.03, p = 0.0036. 
Table 7. Hyperopia: Postoperative Data. Mean postoperative data for the hyperopia cohort and control 
groups. Significance values for statistical analysis between groups are included below the respective data. 
(UCDVA = uncorrected distance visual acuity, BCDVA = best corrected distance visual acuity) 	 Hyperopia	Cohort	 Hyperopia	Control	Group	Follow-up	Time	(Days)	 351	±	92		 369	±	66	p-value	 0.29	Spherical	Power	(D)	 +0.25	±	0.73	 0.060	±	0.42	p-value	 0.045	Cylindrical	Power	(D)	 -0.38	±	0.46	 -0.28	±	0.39	p-value	 0.20	Spherical	Equivalent	(D)	 +0.06D	±	0.78	 -0.08D	±	0.43	p-value	 0.15	UCDVA	(log(MAR))	 0.14	±	0.18	 0.044	±	0.11	p-value	 0.0069	BCDVA	(log(MAR))	 0.03	±	0.07	 .00	±	0.06	p-value	 0.050		
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However, the hyperopia control group’s mean postoperative UCDVA was very 
significantly better than the hyperopia cohort, t(109) = 2.75, p = 0.0069. There was not a 
significant difference between the hyperopia cohort’s mean preoperative and 
postoperative BCDVA, t(62) = -0.61, p = 0.61. There was no significant change to the 
hyperopia control group’s postoperative BCDVA compared to their preoperative 
BCDVA either, t(62) = 1.17, p = 0.27. The mean postoperative BCDVA was not 
significantly different between the groups, t(121) = 1.98, p = 0.050. The breakdown of 
postoperative visual acuities is presented in Figure 8. 
 
The mean postoperative spherical power differed significantly between the 
groups, t(99) = 2.03, p = 0.045. The mean postoperative cylindrical power and spherical 
power did not differ significantly between the groups, t(119) = -1.30, p = 0.20 and t(96) = 
1.45, p = 0.15.  
	
Figure 8. Hyperopia: Cohort vs Control Visual Acuities Representations of the postoperative UCDVA and 
BCDVA of hyperopia cohort and hyperopia control group. The data are in terms of the percentage of eyes 
that achieved that VA or better. 
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Safety 
 Changes in BCDVA are presented in Figure 9. There was no significant 
difference in the distribution of change of BCDVA between the myopia cohort and 
myopia control group, c2(3, N=126) = 0.31, p = 0.96. 
  
Surgery Type 
 In the hyperopia cohort here were 53 eyes that underwent LASIK and 10 eyes that 
underwent ASA. There was no significant difference in mean follow-up time between the 
surgery groups in the hyperopia cohort, t(10) = -1.66, p = 0.13. In the hyperopia control 
group, 48 eyes underwent LASIK and 15 eyes underwent ASA; this was not significantly 
different from the surgery type distribution of the hyperopia cohort, c2(1, N=126) = 0.26, 
p = 0.61. There was no significant difference in mean follow-up time between the surgery 
groups in the hyperopia control group, t(18) = 0.79, p = 0.4. 
 Within the hyperopia cohort, the mean postoperative UCDVA did not differ 
significantly between the eyes that underwent ASA (0.19 ± 0.18) and the eyes that 
underwent LASIK (0.12 ± 0.17), t(11) = 1.03, p = 0.32. The mean postoperative UCDVA 
	
Figure 9. Hyperopia: Change in BCDVA. Representation of the safety profile for both the hyperopia 
cohort and hyperopia control group. The data are presented in terms of the percentage of eyes that 
underwent that change in BCDVA. 
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also did not differ between eyes that underwent ASA (0.07 ±0.13) than eyes that 
underwent LASIK (0.11 ± 0.05) within the hyperopia control group, t(21) = 0.54, p = 
0.60. The mean postoperative BCDVA did not differ significantly between ASA eyes 
(0.03 ± 0.06) and LASIK eyes (0.03 ±0.07) within the hyperopia cohort, t(12) = 0.14, p = 
0.89. In the hyperopia control group, again eyes that underwent ASA (0.02 ± 0.05) did 
not significantly differ than those that underwent LASIK (0.00 ± 0.07) in regard to mean 
postoperative BCDVA, t(27) = 1.21, p = 0.23.  
 Eyes that underwent LASIK within the hyperopia control group had a 
significantly better mean postoperative UCDVA compared to LASIK eyes in the 
hyperopia cohort, t(89) = 2.49, p = 0.015. Likewise, there was a significant difference in 
the mean postoperative BCDVAs when comparing the hyperopia cohort and control 
group’s LASIK eyes, t(97) =  2.04, p = 0.044. When comparing eyes that underwent 
ASA within the hyperopia cohort to ASA eyes in the hyperopia control group, there was 
no significant difference between their mean postoperative UCDVA, t(12) =  1.77, p = 
0.10. Nor was there a difference in the mean postoperative BCDVAs when comparing the 
hyperopia cohort and control group’s ASA eyes, t(15) =  0.43, p = 0.67. 
 
Astigmatism 
 There were 244 eyes (117 right and 127 left eyes) identified with a preoperative 
cylindrical power ≥ -3.50D. Of these, 54 eyes (27 right and 27 left eyes) met the criteria 
for inclusion in the astigmatism cohort. A breakdown of excluded eyes is provided in 
Table 8. There was a total of 15 eyes in the astigmatism cohort that are known to have 
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undergone an enhancement procedure within the year following their surgery, accounting 
for 6.1% of the total eyes that were identified. The mean time after the original surgery 
that the enhancement procedure was performed was 229 ± 123 days.  
 
Preoperative 
Of the 54 eyes included, 29 belonged to men and 25 belonged to women. Average 
preoperative manifest values and visual acuities are presented in Table 9. The myopia 
cohort had three eyes correctable to 20/15 on the Snellen scale, 47 eyes correctable to 
20/20, one eye correctable to 20/25, one eye correctable to 20/30, one eye correctable to 
20/40, and one eye correctable to 20/70. 
Table 8. Astigmatism: Excluded Eyes. A breakdown of the eyes excluded from the astigmatism cohort and for 
what reason. Exclusion	Criteria	 Number	of	Eyes	Excluded	Non-Zero	Target	Refraction	 16	Previous	Surgical	Procedure	 3	Two-Stage	Treatment	 14	Missing	Data	 8	No	Follow-Up	in	Study	Period	
	149	
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The average age at time of surgery did not differ significantly between the 
hyperopia cohort and control group, t(103) = -0.02, p = 0.98. Of the 54 eyes, 27 belonged 
to men and 27 belonged to women; this was not significantly different than the 
astigmatism cohort, c2(1, N=108) = 0.70, p = 0.40. The astigmatism control group was 
very significantly more myopic than the astigmatism cohort, t(103) = 5.97, p = 3.4 x 10-8. 
The mean preoperative cylindrical power of the astigmatism cohort was very 
significantly higher than that of the astigmatism control group, t(61) = -23.52, p = 2.7 x 
10-32. The mean preoperative spherical equivalent of the astigmatism control group very 
significantly more myopic than the hyperopia cohort, t(104) = 3.25, p = 0.0016. The 
mean preoperative BCDVA of the astigmatism control group was very significantly 
better than that of the astigmatism cohort, t(58) = 3.38, p = 0.0013.  
Table 9. Astigmatism: Preoperative Data. Mean preoperative data for the astigmatism cohort and control 
groups. Significance values for statistical analysis between groups are included below the respective data. 
(BCDVA = best corrected distance visual acuity) 	 Astigmatism	Cohort	 Astigmatism	Control	Group	Age	(Years)	 34	±	9	 34	±	9	p-value	 0.98	Spherical	Power	(D)	 0.03D	±	2.78	 -3.14D	±	2.52	p-value	 3.4	x	10-8	Cylindrical	Power	(D)	 -4.18D	±	0.86	 -1.28D	±	0.26	p-value	 2.7	x	10-32	Spherical	Equivalent	(D)	 -2.06	±	2.69	 -3.78D	±	2.51	p-value	 0.0016	BCDVA	(log(MAR))	 0.051	±	0.12	 -0.01	±	0.03	p-value	 0.0013		
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Postoperative 
 
Average postoperative manifest values and visual acuities are presented in Table 
10. The mean follow-up time of the astigmatism control group was very significantly 
later compared to the astigmatism cohort, t(78) = -3.51, p = 7.6 x 10-4. The astigmatism 
cohort’s mean postoperative UCDVA was very significantly worse than its mean 
preoperative BCDVA, t(53) = -3.36, p = 0.0015. There was also a very significant 
decrease in VA between the astigmatism control group’s mean preoperative BCDVA and 
mean postoperative UCDVA, t(53) = -3.47, p = 0.0011. The mean postoperative UCDVA 
of the astigmatism control group was very significantly better than that of the 
astigmatism cohort, t(77) = 3.32, p = 0.0014. There was a very significant improvement 
in VA between the astigmatism cohort’s mean preoperative and postoperative BCDVA, 
t(53) = 3.32, p = 0.0016. There no significant change to the astigmatism control group’s 
postoperative BCDVA compared to their preoperative BCDVA, t(53) = -0.44, p = 0.66. 
 Table 10. Astigmatism: Postoperative Data. Mean postoperative data for the astigmatism cohort and control 
groups. Significance values for statistical analysis between groups are included below the respective data. 
(UCDVA = uncorrected distance visual acuity, BCDVA = best corrected distance visual acuity) 	 Astigmatism	Cohort	 Astigmatism	Control	Group	Follow-up	Time	(Days)	 391	±	50	 340	±	96	p-value	 7.6	x	10-4	Spherical	Power	(D)	 +0.01	±	0.72	 +0.11	±	0.52	p-value	 0.45	Cylindrical	Power	(D)	 -0.73	±	0.97	 -0.29	±	0.40	p-value	 0.0028	Spherical	Equivalent	(D)	 -0.35	±	0.62	 -0.04	±	0.45	p-value	 0.0039	UCDVA	(log(MAR))	 0.12	±	0.19	 0.041	±	0.09	p-value	 0.0014	BCDVA	(log(MAR))	 0.01	±	0.09	 -0.00	±	0.024	p-value	 0.17		
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The mean postoperative BCDVA did not significantly differ between the groups, t(59) = 
1.40, p = 0.17. The breakdown of postoperative visual acuities is presented in Figure 10. 
 
The mean postoperative spherical power did not differ significantly between the 
groups, t(95) = -0.76, p = 0.45. The mean postoperative cylindrical power of the 
astigmatism cohort was very significantly higher than that of the astigmatism control 
group, t(70) = -3.10, p = 0.0028. The mean postoperative spherical equivalent of the 
astigmatism cohort was very significantly higher than that of the astigmatism control 
group, t(96) = -2.98, p = 0.0039.  
Safety 
Changes in BCDVA are presented in Figure 11. There was no significant 
difference in the distribution of change in BCDVA between the astigmatism cohort and 
astigmatism control group, c2(3, N=108) = 0.00, p = 0.99. 
	
Figure 10. Astigmatism: Cohort vs Control Visual Acuities. Representations of the postoperative UCDVA 
and BCDVA of astigmatism cohort and astigmatism control group. The data are in terms of the percentage 
of eyes that achieved that VA or better. 	
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 Surgery Type 
 In the astigmatism cohort here were 43 eyes that underwent LASIK and 11 eyes 
that underwent ASA. There was no significant difference in mean follow-up time 
between the surgery groups in the astigmatism cohort, t(11) = 0.61, p = 0.56 In the 
astigmatism control group, 32 eyes underwent LASIK and 22 eyes underwent ASA; this 
was not significantly different from the surgery type distribution of the astigmatism 
cohort, c2(1, N=108) = 0.02, p = 0.88. There was no significant difference in mean 
follow-up time between the surgery groups in the astigmatism control group, t(11) = 
0.86, p = 0.39. 
 Within the astigmatism cohort, the mean postoperative UCDVA did not differ 
significantly between the eyes that underwent ASA (0.05 ± 0.10) and the eyes that 
underwent LASIK (0.01 ± 0.09), t(13) = 0.73, p = 0.47. The mean postoperative UCDVA 
also did not differ between eyes that underwent ASA (0.06 ±0.09) than eyes that 
underwent LASIK (0.03 ± 0.09) within the astigmatism control group, t(44) = 0.94, p = 
0.35. The mean postoperative BCDVA did not differ significantly between ASA eyes 
	
Figure 11. Astigmatism: Change in BCDVA. Representation of the safety profile for both the 
astigmatism cohort and astigmatism control group. The data are presented in terms of the percentage of 
eyes that underwent that change in BCDVA. 	
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(0.05 ± 0.10) and LASIK eyes (0.01 ±0.09) within the astigmatism cohort, t(13) = 1.14, p 
= 0.27. The mean postoperative BCDVA did not differ significantly between ASA eyes 
(0.01 ± 0.04) and LASIK eyes (0.00 ±0.00) within the astigmatism control group, t(13) = 
-1.45, p = 0.16. 
 Eyes that underwent LASIK within the astigmatism control group had a very 
significantly better mean postoperative UCDVA compared to LASIK eyes in the 
astigmatism cohort, t(64) = 2.81, p = 0.0066. However, there was no significant 
difference in the mean postoperative BCDVAs when comparing the astigmatism cohort 
and control group’s LASIK eyes, t(41) =  0.45, p = 0.66. When comparing eyes that 
underwent ASA within the astigmatism cohort to ASA eyes in the astigmatism control 
group, there was no significant difference between their mean postoperative UCDVA, 
t(11) =  1.79, p = 0.10. Nor was there a difference in the mean postoperative BCDVAs 
when comparing the astigmatism cohort and control group’s ASA eyes, t(10) =  1.75, p = 
0.11. 
 
Outlier Cohorts 
 The visual outcomes of the myopia cohort, hyperopia cohort, and astigmatism 
cohort were compared. There was no significant difference in postoperative UCDVA 
between the cohorts, F(2,162) = 2.03, p = 0.36. There was no significant difference in 
postoperative BCDVA between the cohorts, F(2,162) = 0.48, p = 0.62. There was no 
significant difference in the distribution of changes to BCDVA (Figure 12) between pre- 
and postoperative measurements, c2(8, N=165) = 2.3 x 10-4, p = 1.00.  
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Figure 12. All Cohorts: Change in BCDVA. Representation of the safety profile for both the myopia 
cohort, hyperopia cohort, and astigmatism cohort. The data are presented in terms of the percentage of 
eyes that underwent that change in BCDVA. 	
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DISCUSSION 
 
Myopia 
 The myopia cohort was chosen to include only those with a substantially high 
degree of myopia (≥ -8.50D) without concern for their degree of astigmatism. The age 
matching of mild-moderate myopes was successful as their mean age did not differ 
significantly that of the myopia cohort. The myopia control group did have a significantly 
longer follow-up time than the myopia cohort. The myopia cohort’s mean follow-up time 
of almost one year (361 days) should have been more than sufficient to allow for 
stabilization of vision postoperatively (Keskinbora), and thusly the difference in follow-
up time should not have affected the comparison of visual outcomes (Keskinbora). As 
designed, the myopia cohort’s preoperative spherical power and spherical equivalent 
were very significantly more negative than the myopia control group. It should be noted 
that the myopia control group had significantly higher preoperative mean cylindrical 
power than the myopia cohort. This was likely due to not controlling for degree of 
astigmatism when including eyes in either the myopia cohort or control group. Its 
possible impact is discussed below. 
 The main goal of refractive surgery being to reduce patient’s reliance on glasses, 
the best outcomes would be to have their postoperative UCDVA match or be better than 
their preoperative BCDVA. The myopia cohort experienced a very significant decrease in 
VA when comparing their preoperative BCDVA to their postoperative UCDVA. This 
differed from the myopia control group which did not experience any significant change 
when comparing the same variables and had a significantly better postoperative UCDVA 
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than the myopia cohort. That is, the myopia control group had better vision than the 
myopia cohort after surgery. Additionally, the myopia cohort did not see as well as they 
did with their correction prior to surgery. This is a similar result to Kojima et al. that also 
found that lower myopes achieved a better postoperative UCDVA than high myopes. It is 
worth mentioning the myopia cohort of this thesis had a more myopic mean preoperative 
spherical equivalent (-8.77D vs – 7.54D) than that in Kojima et al. It would be expected 
that the myopia cohort would achieve a less ideal vision postoperatively because of this 
but the cohort achieved a better mean postoperative UCDVA than Kojima et al.’s 
myopes.  
While there was no significant difference in residual spherical power, the myopia 
cohort did have significantly more residual cylindrical power which accounts for the 
difference in UCDVA. This is interesting due to the myopia control group having higher 
preoperative cylindrical power. It is possible that the treatment pattern of the higher 
myopes was less effective in treating astigmatic errors than the treatment pattern of lower 
myopes. Another possible explanation is that the treatment of higher myopes had a higher 
probability of inducing a new or different astigmatism to a greater degree than the 
treatment of low myopes. Further investigation may be warranted to differentiate between 
these possibilities.  
 The myopia cohort’s mean BCDVA postoperatively was significantly worse than 
their preoperative mean BCDVA with 13% of eyes losing lines of BCDVA. The myopia 
control group experienced no corresponding changes to their BCDVA after surgery and 
had a very significantly better mean BCDVA than the myopia cohort. In other words, the 
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myopia cohort could not see as well after surgery as they did before, even with the use of 
corrective lenses.  
However, from a safety standpoint, there was no significant difference in the 
distribution of the change in Snellen lines of BCDVA. This means that eyes in the 
myopia control group, with low-moderate myopia, were just as likely to lose lines of 
vision as cohort eyes, with high myopia. Similarly, highly myopic eyes were just as likely 
to gain vision lines of vision as low-moderate myopic eyes.  
The UCDVA and BCDVA results did not differ significantly between eyes that 
underwent different surgeries for eyes in the myopia cohort. In contrast, eyes underwent 
ASA in the myopia control group had significantly better outcomes for UCDVA and 
BCDVA than the eyes that underwent LASIK. This result differed from Helmy et al. and 
Hashemi et al. which both found LASIK to be superior to PRK (ASA) for high myopes. 
Their studies included a wider range of high myopes, -6.00D and -10.00D (Helmy et al.) 
and >-7.00D (Hashemi et al.) than this thesis. The restriction of the myopia cohort to 
comparatively very high myopes may have influenced this result in that the visual 
outcomes of both surgery types were poor and a difference in efficacy could not be 
distinguished.  
 Refractive surgery was effective in reducing the refractive error of the high 
myopia cohort of this thesis, 100% of cohort eyes were able to reach 20/40 or better with 
correction and 92% without correction. However, their results were not as ideal as the 
control group, with only 63% of eyes reaching 20/20 or better uncorrected vs 83%, and 
100% of control eyes being correctable to 20/20 or better. The myopia cohort performed 
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better than those in Keskinbora which reported a peak of 22.5% of eyes achieving 20/20 
or better and 90% achieving 20/40 or better uncorrected. However, Reinstein et al. 
reported better outcomes for their high myopia group than the high myopia cohort in this 
thesis with 89% of eyes 20/20 or better and 99% 20/40 or better uncorrected. The cohort 
reached an UCDVA of 20/~25 and a BCDVA of 20/~21 vs the control group’s 20/~21 
and 20/~19. Both groups achieved satisfactory results, with the control group achieving 
better vision.  
 LASIK and ASA were safe and provided similar, satisfactory results for those 
with significantly high myopia, but these patients should be counseled as to the risk that 
their results may not be as ideal as their lower myopia counterparts.  
 
Hyperopia 
 The hyperopia cohort was chosen to include eyes with a moderately high degree 
of hyperopia without concern for degree of astigmatism. The age matching of the 
hyperopia control group was successful. As designed the hyperopia cohort had very 
significantly more hyperopic mean preoperative spherical power and spherical equvalent 
than the hyperopia control group. 
 Both the hyperopia cohort and control group showed a very significant decrease 
in vision when comparing their preoperative UCDVA and postoperative UCDVA. 
However, when comparing the two groups’ UCDVA postoperatively, the hyperopia 
control group had very significantly better uncorrected vision. It has been previously 
demonstrated that visual outcomes in hyperopic LASIK are negatively influenced by the 
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degree of hyperopic correction (Cobo-Soriano et al.). This study’s findings seem to 
concur, with the hyperopic control group having significantly better mean UCDVA and 
BCDVA after surgery.  
The hyperopia cohort demonstrated a small amount of under-correction with their 
mean postoperative spherical power being left slightly hyperopic (spherical power = 
+0.25D). While the hyperopia control group demonstrated an almost negligible amount 
of over-correction with the spherical power being left slightly myopic (spherical power = 
-0.060D). The small under-correction of the hyperopia cohort and the over-correction of 
the hyperopia control group correspond with each groups’ respective UCDVA after 
surgery. These residual refractive errors can be reasonably assumed to be causative of 
their non-ideal postoperative UCDVAs.  
Neither the hyperopia cohort, nor the control group, experienced a significant 
change in their mean BCDVA when comparing preoperative and postoperative values. 
There was also no significant difference between the hyperopic groups’ postoperative 
BCDVA. Meaning that with correction both groups saw as well as they did before 
surgery. There was also no difference in the distribution of Snellen lines gained/lost. 
Thus, the hyperopia cohort was not at greater risk of losing or gaining vision. Published 
literature on high hyperopes shows rates of losing BCDVA between 10% (Alió et al.) and 
17.5% (Plaza-Puche et al.), consistent with the 10% of eyes in the hyperopia cohort that 
lost vision. Refractive surgery was as safe for high hyperopes as for low hyperopes. 
With only 40% of eyes achieving 20/20 or better and 87% achieving 20/40 or 
better vision uncorrected, the hyperopia cohort did not have ideal results. In the 
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hyperopic control group, 62% of eyes achieved 20/20 or better vision and 97% achieved 
20/40 or better vision uncorrected, which were not ideal either. The cohort reached an 
UCDVA of 20/~27 and a BCDVA of 20/~21 vs the control group’s 20/~23 and 20/~20. 
Both groups achieved satisfactory results, with the control group achieving better vision. 
LASIK and ASA were safe and provided similar, satisfactory results for those with 
significantly high hyperopia, but these patients should be counseled as to the risk that 
their results may not be as ideal as their lower hyperopia counterparts.   
 
Astigmatism 
 The astigmatism cohort was chosen to include eyes with a high degree of 
astigmatism. The age matching of the astigmatism control group was successful. The 
astigmatism cohort had a significantly shorter mean follow-up time, but as previously 
discussed at 340 days it likely did not impact the visual outcomes. As designed, there was 
a significant difference between the astigmatism cohort and control group’s mean 
preoperative cylindrical power and spherical equivalent. However, there was also a very 
significant difference between their preoperative spherical power as well, with both 
groups having an average moderate amount of myopia. This did not likely effect the 
visual outcomes of the groups.  
 The astigmatism cohort experienced a very significant loss of vision when 
comparing their mean preoperative BCDVA to mean postoperative UCDVA. There was a 
corresponding very significant decrease in the astigmatism control groups vision 
comparing the same variables. The control group’s mean postoperative UCDVA was still 
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very significantly better than that of the astigmatism cohort. These results correlate to the 
residual refractive errors of the two groups with the cohort left with an average of -0.73 ± 
0.97 cylindrical power and an average spherical equivalent of -0.35D ± 0.62, compared to 
-0.29D ± 0.40 and -0.04D ± 0.45, respectfully, for the control group. The undercorrection 
of the astigmatism cohort is similar to previously reported high astigmatism groups 
(residual cylindrical power = -0.97D & -1.17D) (Ivarsen et al.). Both the astigmatism 
cohort and control group had worse vision after surgery, but the control group still saw 
better than the cohort.  
 With correction the astigmatism control group could see just as well as they did 
before the surgery. Furthermore, with correction the control group did not see better than 
the cohort did. The astigmatism cohort had a very significant improvement to their 
BCDVA. After surgery the cohort was able to be corrected to better vision than they had 
prior to surgery. This is demonstrated by the 27% of eyes in the astigmatism cohort that 
gained Snellen lines of BCDVA.  
The astigmatism control group had 77% of eyes achieving 20/20 or better and 
100% achieving 20/40 or better uncorrected; while in the astigmatism cohort only 44% of 
eyes achieved 20/20 or better and 89% achieved 20/40 or better uncorrected, 98% of eyes 
were correctible to 20/40 or better. This was a significant increase from the 96% of eyes 
correctable to 20/40 or better preoperatively. The cohort reached an UCDVA of 20/~27 
and a BCDVA of 20/~21 vs the control group’s 20/~22 and 20/~20. Both groups 
achieved satisfactory results, with the control group achieving better vision.  
	51 
 Within both the astigmatism cohort and control group there was no difference in 
UCDVA or BCDVA when comparing eyes that underwent ASA vs LASIK. This is 
consistent with a previous report which found LASIK and PRK to be comparably 
effective treatment of high astigmatism (Katz et al.). The astigmatism cohort also 
included those that with higher degrees of astigmatism than Katz et al.’s group, >-3.50D 
vs >-3.00D.  
 LASIK and ASA proved to provide similar, satisfactory results for those with 
high astigmatism. There was also theoretical potential for the astigmatism cohort to gain 
BCDVA, if repeat surgeries were to be performed. There was no difference in the 
distribution of loss/gain of BCDVA between the astigmatism cohort and control groups 
which demonstrated similar safety profiles. However, due to the results of the 
postoperative UCDVA and BCDVA, those with high astigmatism should be cautioned 
that they may have worse visual results than their lower astigmatism peers. 
 
Outlier Cohorts 
 The analysis of postoperative vision between cohorts revealed no significant 
differences. The cohorts had similar mean postoperative UCDVAs, as well as mean 
postoperative BCDVAs. The safety profiles of each cohort showed no significant 
differences. Overall, none of the cohorts were able to gain ideal, uncorrected vision, but 
they achieved similar satisfactory results.  
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Limitations and Future Studies 
 A prominent limitation of this study was that there was no control for 
confounding refractive errors. This was most obvious in the myopia category. This could 
be avoided in future investigations by setting limits the preoperative spherical power for 
astigmatism groups and preoperative cylindrical power for myopia and hyperopia groups. 
Another limitation was the limited study period which yielded only moderate 
sample sizes. Refractive and visual stabilization theoretically should have occurred three 
to six months after surgery, and inclusion of data from follow-up visits after that time 
could have yielded larger sample sizes. More significant sample sizes would increase the 
power of the study, while also reduce the chances of sampling error.  
The limited study period may have also skewed the result data for the population. 
It can be reasonably assumed that happy patients, or those with good visual outcomes, 
were less likely to attend follow-up appointments. Therefore, the true final visual 
outcomes for these populations may be better than reported here.  
While standard follow-up visits were attempted to be made for all patients, there 
was a lack of compliance. It is also possible that the follow-up visits were not consistent 
across all patients; more specifically that during VA testing and manifest refraction the 
technician may not have asked all patients able to read the 20/20 line to read the 20/15 
line. A future prospective study should allow for greater control and standardization over 
follow-up visits. Any future study should also include manifest refractions at all visits to 
allow for tracking of the stability of refractions.  
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In conclusion, LASIK and ASA are safe for outlier candidates with high myopia, 
high hyperopia, or high astigmatism. Neither surgery type offered superior results for the 
high refractive error cohorts. There was no difference in visual outcomes or safety for 
outliers with different refractive errors. While these surgeries offer satisfactory results, 
the candidates should be properly informed that they may achieve poorer results than 
counterparts with lower degrees of refractive error.   
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